The Patent Trial and Appeal Board didn’t err in changing its mind about whether to review a patent’s validity in the wake of a U.S. Supreme Court ruling, the Federal Circuit said Aug. 29.
The PTAB must either grant or deny a petition for inter partes review in its entirety, the Supreme Court said in SAS Institute v. Iancu. In order to comply with that decision, it could reverse a partial grant, the U.S. Court of Appeals for the Federal Circuit said.
BioDelivery Sciences International Inc. filed three petitions for IPR of an Aquestive Therapeutics Inc. patent. The petitions ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.